Company / Working Capital
Atea Pharmaceuticals, Inc. Working Capital History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$642.4M
FY2022
5-year range
$547.7M / $715.5M
FY2020-FY2022
Trend
-10.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $548M to $642M over the past 2 years.
Based on SEC 10-K filings.
$642M in FY2022.
Improved from $548M to $642M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, working capital decreased 10.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $642.4M | -10.2% |
| FY2021 | $715.5M | +30.6% |
| FY2020 | $547.7M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026